Benjamin Kreitman

Benjamin Kreitman, is a Principal at Broadview Ventures.

Benjamin shares responsibility for the day-to-day investment activities at Broadview Ventures, including identification and screening of new opportunities, due diligence, negotiation of deal structure, and portfolio company board involvement. Benjamin serves on the Board of Directors of HAYA Therapeutics.

Prior to joining Broadview, Benjamin was a Consultant at Monitor Deloitte, the strategy management consulting arm of Deloitte Consulting, LLP. At Monitor Deloitte, Benjamin worked alongside senior executives on a variety of engagements including commercial strategy development for biotechnology startups as well as global pharmaceutical and medical device manufacturers, and corporate development and investment due diligence across a number of industries.

Benjamin earned undergraduate degrees in Biological Sciences and Financial Economics Magna Cum Laude from Columbia University.